Illumina (NASDAQ:ILMN) Director Keith Meister Sells 62,691 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 62,691 shares of the firm’s stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $215.48, for a total value of $13,508,656.68. Following the completion of the transaction, the director directly owned 307,659 shares in the company, valued at $66,294,361.32. The trade was a 16.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Illumina Stock Down 1.6%

ILMN opened at $209.55 on Friday. The firm has a market cap of $31.68 billion, a P/E ratio of 40.56, a price-to-earnings-growth ratio of 2.89 and a beta of 1.46. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.05 and a current ratio of 2.63. The business has a 50 day moving average price of $249.32 and a 200 day moving average price of $179.36. Illumina, Inc. has a twelve month low of $112.65 and a twelve month high of $309.35.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The company had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.15 billion. During the same quarter last year, the company posted $1.34 earnings per share. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. Research analysts forecast that Illumina, Inc. will post 5.43 EPS for the current year.

Key Headlines Impacting Illumina

These are some of the ILMN headlines that stood out recently:

• Positive Sentiment: Illumina reported third-quarter revenue of $1.129 billion and net income of $220 million, raised its 2026 revenue outlook to $4.64 billion–$4.66 billion, and highlighted strength in clinical sequencing consumables. How Investors May Respond To Illumina (ILMN) Earnings Beat
• Positive Sentiment: The company expanded its molecular residual disease research portfolio with an ultrasensitive duplex sequencing workflow for circulating tumor DNA and was selected to provide whole-genome sequencing services for Singapore’s SG-INSIGHT precision-medicine study. These developments support its push into clinical oncology and sequencing applications. Illumina (ILMN) Unveils Duplex Sequencing Workflow For MRD Research
• Negative Sentiment: Director Keith Meister sold 280,091 shares over November 9–11 for approximately $61.1 million, reducing his direct holdings to 208,826 shares. The scale of the sales could raise concerns among investors, despite his continuing substantial ownership. SEC filing

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. N.F.U. MUTUAL UNIT MANAGERS Ltd acquired a new stake in shares of Illumina in the third quarter worth $2,802,000. Gabelli Funds LLC raised its stake in Illumina by 2.0% during the 3rd quarter. Gabelli Funds LLC now owns 5,100 shares of the life sciences company’s stock valued at $1,396,000 after purchasing an additional 100 shares during the last quarter. Meeder Advisory Services Inc. raised its stake in Illumina by 6.7% during the 3rd quarter. Meeder Advisory Services Inc. now owns 2,987 shares of the life sciences company’s stock valued at $817,000 after purchasing an additional 187 shares during the last quarter. NWK Group Inc. acquired a new position in Illumina during the 3rd quarter valued at $7,202,000. Finally, Allianz SE bought a new stake in Illumina in the 3rd quarter valued at $249,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Canaccord Genuity Group raised their target price on shares of Illumina from $205.00 to $300.00 and gave the company a “hold” rating in a research note on Monday, October 19th. Royal Bank Of Canada upped their price target on shares of Illumina from $230.00 to $310.00 and gave the company an “outperform” rating in a report on Monday, October 5th. Citigroup upped their price target on shares of Illumina from $113.00 to $210.00 and gave the company a “sell” rating in a report on Monday, November 2nd. Weiss Ratings raised Illumina from a “hold (c)” rating to a “buy (b-)” rating in a research report on Monday, November 2nd. Finally, Guggenheim lifted their price objective on Illumina from $226.00 to $305.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $244.24.

Illumina Company Profile

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.